L

Lycia Therapeutics, Inc.

LYCAPriced

Lycia Therapeutics, Inc. · Nasdaq Global Market · Research source · S-1 · 2026-10-05 · Latest filing · 8-K · 2026-10-26 SEC ↗

Report source
Research source · S-1 · 2026-10-05
SummaryBASIC RESEARCHReport source · S-1

Lycia’s preliminary IPO remains incomplete, with blank pricing, share counts, proceeds and listing approval pending.

As of the October 5, 2026 preliminary prospectus, Lycia had not disclosed IPO pricing or share counts and had no public market.

Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointEffectiveness of the registration statement, pricing and any confirmed listing or trading commencement are not disclosed.S-1 · 2026-10-05
Business and development direction

Lycia Therapeutics, Inc.

Current business
Future development
DECISION DRIVERS

Key risks

Risk 1

Lycia has limited operating history, no approved products and has not completed any clinical trials, making success difficult to evaluate.

Risk 2

The company expects significant future losses and substantial additional capital; failure to raise funds could delay or eliminate programs.

Risk 3

Clinical, regulatory, intellectual-property and third-party manufacturing failures could prevent commercialization or increase costs and delays.

Next checkEffectiveness of the registration statement, pricing and any confirmed listing or trading commencement are not disclosed.
Latest filing2026-10-26
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualitySource-linked structured inputs are not yet available. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
PRELIMINARY
#InstitutionUnderwriting allocationRatioShares
1Jefferies LLC
2TD Securities (USA) LLC
3Evercore Group L.L.C.
4Guggenheim Securities, LLC
5LifeSci Capital, LLC
6Jefferies
7TD Cowen
8Evercore ISI
9Guggenheim Securities
10Passive Book-Running Manager
11LifeSci Capital
Source and calculation

Names are explicitly identified in source underwriting tables or role clauses. Quantities require the named firm's own table row; missing allocations are not inferred.

Source · S-1 ↗

IPO CAPITAL QUALITY

Issuer capital
Selling-holder liquidity
Primary shares
Secondary shares
Basis and evidence

S-1 · 2026-10-05

As of the October 5, 2026 preliminary prospectus, Lycia had not disclosed IPO pricing or share counts and had no public market.

Offering structure

Source and calculation
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Use of proceedsSource-linked structured inputs are not yet available. Open filing ↗

Dilution and valuation

IPO price—
Basic post-offer—
Equity value—

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Open filing ↗
Basis and evidence ↗

Share-count comparison

Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Source inputs required

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Source ↗
Implied equity value—Price × post-offer shares
Post-offer shares—Share count, not tradable float
Existing-holder ownership reduction—Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Base post-offer shares

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Equity value

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Share-count change

Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.

Alternative scenarios

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Sensitivity

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesSource-linked structured inputs are not yet available. Open filing ↗
As of
2026-10-05
!The supplied evidence states that existing insiders and 5% holders will retain significant voting influence, but percentages and holder-level amounts are blank or incomplete.View source ↗
Relationship filters
Show
share structure
Select for details · Lycia Therapeutics, Inc.
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLCOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Redmile Biopharma Investments III, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Venrock Healthcare Capital Partners EG, L.P. and Venrock Healthcare Capital Partners XP, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Janus Henderson Biotech Innovation Master Fund LimitedOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
entities with which certain of our directors are affiliatedOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partitionDisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicableDisclosedEvidence
Source and calculation ↗
Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLC · Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLC — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(1)Consists of shares of our Series C Preferred Stock purchased by Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLC, which together beneficially own more than 5% of our outstanding capital stock.

0001628280-26-064973 · SEC ownership paragraph; source 1615333:1615913; SHA256 07b6582f0496dc7b039e18e1f78288701b603c5d2aa8fa4a17998d9654d23f4b ↗

RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd. · RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(2)Consists of shares of our Series C Preferred Stock purchased by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd., which together beneficially own more than 5% of our outstanding capital stock.

0001628280-26-064973 · SEC ownership paragraph; source 1615913:1616462; SHA256 d486b8532295ccd6804ab365719921896146376ab13140f725e00274cca324f7 ↗

Redmile Biopharma Investments III, L.P. · Redmile Biopharma Investments III, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(3)Consists of shares of our Series C Preferred Stock purchased by Redmile Biopharma Investments III, L.P., which beneficially owns more than 5% of our outstanding capital stock. Ming Fang, a member of our board of directors, is affiliated with Redmile Biopharma Investments III, L.P.

0001628280-26-064973 · SEC ownership paragraph; source 1616462:1617047; SHA256 26c09baf16a27a344ae251b81b41e9bc861bc00a3c21da73a099d1ba94fbd013 ↗

Venrock Healthcare Capital Partners EG, L.P. and Venrock Healthcare Capital Partners XP, L.P. · Venrock Healthcare Capital Partners EG, L.P. and Venrock Healthcare Capital Partners XP, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(1)Consists of shares of our Series D Preferred Stock purchased by Venrock Healthcare Capital Partners EG, L.P. and Venrock Healthcare Capital Partners XP, L.P., which together beneficially own more than 5% of our outstanding capital stock.

0001628280-26-064973 · SEC ownership paragraph; source 1625866:1626407; SHA256 0c50f9e790f985e463ef5289bfdadced867fc5f55f492efef79371f634a5184d ↗

RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd. · RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(2)Consists of shares of our Series D Preferred Stock purchased by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd., which together beneficially own more than 5% of our outstanding capital stock.

0001628280-26-064973 · SEC ownership paragraph; source 1626407:1626956; SHA256 421cbe3067add4723bedfbef90b4a1caa9c52b5ee2f041b174f1ada2e6ed1086 ↗

Janus Henderson Biotech Innovation Master Fund Limited · Janus Henderson Biotech Innovation Master Fund Limited — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(3)Consists of shares of our Series D Preferred Stock purchased by Janus Henderson Biotech Innovation Master Fund Limited, which beneficially owns more than 5% of our outstanding capital stock.

0001628280-26-064973 · SEC ownership paragraph; source 1626956:1627470; SHA256 623719b0a874615a0311dc0af6c40353b1949f7caebf612783cefe823fe9a425 ↗

entities with which certain of our directors are affiliated · entities with which certain of our directors are affiliated — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition

In connection with our Series D Preferred Stock Financing, we entered into the IRA with certain holders of our convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding common stock. Under the IRA, these stockholders are entitled to rights with respect to the registration of their shares under the Securities Act following this offering, and the provisions relating to registration rights included in the IRA will not terminate as a result of this offering. See the section titled “Description of Capital Stock—Registration Rights” for additional information.

0001628280-26-064973 · SEC ownership paragraph; source 1627670:1628487; SHA256 4d975014cdda7ad2d58667b0e863a6f42e2e3c8e63bf2fc1eef30dab85f540bf ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Source context: The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it does not contain all the information that may be important to you. We expect to adopt a restated certificate of incorporation and restated bylaws that will become effective upon the completion of this offering, and this description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.

0001628280-26-064973 · SEC ownership excerpt; source 1681445:1682292; SHA256 43b6fdf3252f74a7bf5b75911ff21af0bc5eef0b4610d2b4e0800e47d4124ec4; context source 1677753:1678636; SHA256 62c68b4bef16154b4879809e1f54b12b45e87ceb4b40a59ed09a02cb962d2a36 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

Share supply

Conditional lock-up duration

Company, officers, directors and holders of substantially all securities; after date of prospectus

Conditional lock-up duration
MeasureReported value
Conditional lock-up duration180 days
Source and calculation
Conditional lock-up duration

Company, officers, directors and holders of substantially all securities; after date of prospectus

SHARES ELIGIBLE FOR FUTURE SALE ↗

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
Each of our officers, directors and substantially all of our stockholdersAfter date of this prospectus · Source conditions apply180 days
We, our officers, directors and holders of substantially all of our securities,After date of this prospectus · Source conditions apply180 days
Source and calculation
Each of our officers, directors and substantially all of our stockholders

Based on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.

SEC lock-up paragraph; source 693851:695920; SHA256 f452dcb2f163012b8d06835ace45dcfe70f773d9be10b82832dea01db77e12fe ↗
We, our officers, directors and holders of substantially all of our securities,

We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”

SEC lock-up paragraph; source 1724951:1726308; SHA256 1d6399656e9544a0323570188a3e73821568a4f321ed2a6dc66e46fd6da3aa50 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

date of this prospectus

  1. Each of our officers, directors and substantially all of our stockholdersBased on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.
  2. We, our officers, directors and holders of substantially all of our securities,We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”
Holder / event
Holder / eventTerm / dateConditions
Each of our officers, directors and substantially all of our stockholders180 daysBased on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.
We, our officers, directors and holders of substantially all of our securities,180 daysWe, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”
Basis and evidence
Each of our officers, directors and substantially all of our stockholders

Based on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.

SEC lock-up paragraph; source 693851:695920; SHA256 f452dcb2f163012b8d06835ace45dcfe70f773d9be10b82832dea01db77e12fe ↗
We, our officers, directors and holders of substantially all of our securities,

We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”

SEC lock-up paragraph; source 1724951:1726308; SHA256 1d6399656e9544a0323570188a3e73821568a4f321ed2a6dc66e46fd6da3aa50 ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported
FY2024($26,503,000)
FY2025($36,460,000)
Financial quality
CalculationFY2024FY2025
Net income / (loss)($26,503,000)($36,460,000)
Financial quality
CalculationReported value
Cash and cash equivalents2024-12-31$30,591,000
Cash and cash equivalents2025-12-31$19,268,000
Current assets2024-12-31$139,828,000
Current assets2025-12-31$80,632,000
Total assets2024-12-31$150,911,000
Total assets2025-12-31$97,215,000
Current liabilities2024-12-31$23,327,000
Current liabilities2025-12-31$6,486,000
Total liabilities2024-12-31$26,499,000
Total liabilities2025-12-31$8,213,000
Total equity / (deficit)2024-12-31($77,929,000)
Total equity / (deficit)2025-12-31($113,339,000)
Cash and cash equivalents2025-12-31 · Unaudited$19,268,000
Cash and cash equivalents2026-06-30 · Unaudited$60,940,000
Current assets2025-12-31 · Unaudited$80,632,000
Current assets2026-06-30 · Unaudited$127,719,000
Total assets2025-12-31 · Unaudited$97,215,000
Total assets2026-06-30 · Unaudited$156,760,000
Current liabilities2025-12-31 · Unaudited$6,486,000
Current liabilities2026-06-30 · Unaudited$10,138,000
Total liabilities2025-12-31 · Unaudited$8,213,000
Total liabilities2026-06-30 · Unaudited$11,845,000
Total equity / (deficit)2025-12-31 · Unaudited($113,339,000)
Total equity / (deficit)2026-06-30 · Unaudited($132,141,000)
Net income / (loss)6M ended 2025-06-30 · Unaudited($25,624,000)
Net income / (loss)6M ended 2026-06-30 · Unaudited($19,196,000)
Basis and evidence
Cash and cash equivalents
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Net loss
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Cash and cash equivalents
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total stockholders’ deficit
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Net loss
6M ended 2025-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2025-06-30
Net loss
6M ended 2026-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2026-06-30
Financial quality and runway
Financial review

Financial quality and runway

The latest supplied actual financial period is the six months ended June 30, 2026, supplemented by cash as of that date; the September 30 estimate is blank and unaudited.

Cash and cash equivalents$30,591,000
Cash and cash equivalents$19,268,000
Total current assets$139,828,000
EvidenceFinancial review 1

Six-month 2026 collaboration revenue was $0 and net loss was $19.196 million, with figures presented in thousands.

EvidenceFinancial review 2

Cash, cash equivalents and marketable securities were $148.1 million as of June 30, 2026.

EvidenceFinancial review 3

The company states it has incurred significant operating losses and has not generated product-sales revenue.

LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open S-1 ↗

No source-comparable material changes identified in this report.

IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.

Loading filing history…

Risk 1

Lycia has limited operating history, no approved products and has not completed any clinical trials, making success difficult to evaluate.

Risk 2

The company expects significant future losses and substantial additional capital; failure to raise funds could delay or eliminate programs.

Risk 3

Clinical, regulatory, intellectual-property and third-party manufacturing failures could prevent commercialization or increase costs and delays.

DocumentS-10001628280-26-064973
Filed2026-10-05SEC EDGAR
Research updated2026-10-06Analysed
Source-bound table inputs28SEC EDGAR
Open filing ↗